BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise

Reuters01-08

BUZZ-<a href="https://laohu8.com/S/PHAT">Phathom Pharmaceuticals</a> drops after announcing planned equity raise

** Phathom Pharmaceuticals PHAT.O shares down 10.1% post-market at $16.25 after planned equity raise news

** Gastrointestinal (GI) diseases-focused biopharma announces offering comprised of stock and pre-funded warrants; deal size not disclosed

** Co intends to use net offering proceeds for general corporate purposes, including for working capital and commercialization and R&D expenses

** Guggenheim and Cantor Fitzgerald joint bookrunners

** Co also says expects Q4 net revenues of approx $57-$58 mln and cash of about $130 mln as of Dec 31

** With ~71.1 mln shares outstanding, it has ~$1.3 bln market cap

** PHAT shares on Weds ended up 10.4% at $18.08, up 9% to start 2026. Stock roughly doubled in 2025

** 9 of 10 analysts covering rate the stock "strong buy" or "buy", 1 "hold"; median PT $23, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601814143?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 05:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601814143","market":"fut","top_or_hot":-1,"title":"BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/PHAT\">Phathom Pharmaceuticals</a> drops after announcing planned equity raise</title></head><body><p>** Phathom Pharmaceuticals <span>PHAT.O</span> shares down 10.1% post-market at $16.25 after planned equity raise news</p><p>** Gastrointestinal (GI) diseases-focused biopharma announces offering comprised of stock and pre-funded warrants; deal size not disclosed</p><p>** Co intends to use net offering proceeds for general corporate purposes, including for working capital and commercialization and R&amp;D expenses</p><p>** Guggenheim and Cantor Fitzgerald joint bookrunners</p><p>** Co also says expects Q4 net revenues of approx $57-$58 mln and cash of about $130 mln as of Dec 31</p><p>** With ~71.1 mln shares outstanding, it has ~$1.3 bln market cap</p><p>** PHAT shares on Weds ended up 10.4% at $18.08, up 9% to start 2026. Stock roughly doubled in 2025</p><p>** 9 of 10 analysts covering rate the stock \"strong buy\" or \"buy\",  1 \"hold\"; median PT $23, per LSEG data</p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 05:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-<a href=\"https://laohu8.com/S/PHAT\">Phathom Pharmaceuticals</a> drops after announcing planned equity raise</title></head><body><p>** Phathom Pharmaceuticals <span>PHAT.O</span> shares down 10.1% post-market at $16.25 after planned equity raise news</p><p>** Gastrointestinal (GI) diseases-focused biopharma announces offering comprised of stock and pre-funded warrants; deal size not disclosed</p><p>** Co intends to use net offering proceeds for general corporate purposes, including for working capital and commercialization and R&amp;D expenses</p><p>** Guggenheim and Cantor Fitzgerald joint bookrunners</p><p>** Co also says expects Q4 net revenues of approx $57-$58 mln and cash of about $130 mln as of Dec 31</p><p>** With ~71.1 mln shares outstanding, it has ~$1.3 bln market cap</p><p>** PHAT shares on Weds ended up 10.4% at $18.08, up 9% to start 2026. Stock roughly doubled in 2025</p><p>** 9 of 10 analysts covering rate the stock \"strong buy\" or \"buy\",  1 \"hold\"; median PT $23, per LSEG data</p><p>(Lance Tupper is a Reuters market analyst. The views expressed are his own)</p><p>((lance.tupper@tr.com 1-646-279-6380))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nL6N3Y817W:1","article_id":"2601814143","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601814143","pubTimestamp":1767822905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise** Phathom Pharmaceuticals PHAT.O shares down 10.1% post-market at $16.25 after planned equity raise news** Gastrointestinal  diseases-focused biopharma announces offering comprised of stock and pre-funded warrants; deal size not disclosed** Co intends to use net offering proceeds for general corporate purposes, including for working capital and commercialization and R&D expenses** Guggenheim and Cantor Fitzgerald joint bookrunners** Co also says expects Q4 net revenues of approx $57-$58 mln and cash of about $130 mln as of Dec 31** With ~71.1 mln shares outstanding, it has ~$1.3 bln market cap** PHAT shares on Weds ended up 10.4% at $18.08, up 9% to start 2026. Stock roughly doubled in 2025** 9 of 10 analysts covering rate the stock \"strong buy\" or \"buy\",  1 \"hold\"; median PT $23, per LSEG data","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PHAT":"Phathom Pharmaceuticals"},"translate_title":"BUZZ-Phathom Pharmaceuticals宣布计划股权融资后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHAT":0.9},"content_text":"BUZZ-Phathom Pharmaceuticals drops after announcing planned equity raise** Phathom Pharmaceuticals PHAT.O shares down 10.1% post-market at $16.25 after planned equity raise news** Gastrointestinal (GI) diseases-focused biopharma announces offering comprised of stock and pre-funded warrants; deal size not disclosed** Co intends to use net offering proceeds for general corporate purposes, including for working capital and commercialization and R&D expenses** Guggenheim and Cantor Fitzgerald joint bookrunners** Co also says expects Q4 net revenues of approx $57-$58 mln and cash of about $130 mln as of Dec 31** With ~71.1 mln shares outstanding, it has ~$1.3 bln market cap** PHAT shares on Weds ended up 10.4% at $18.08, up 9% to start 2026. Stock roughly doubled in 2025** 9 of 10 analysts covering rate the stock \"strong buy\" or \"buy\",  1 \"hold\"; median PT $23, per LSEG data(Lance Tupper is a Reuters market analyst. The views expressed are his own)((lance.tupper@tr.com 1-646-279-6380))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601814143","isCrawlerRequest":true}